NVO

Novo Nordisk A/S

Healthcare · Pharmaceuticals · NYSE (ADR)
$43.88
Data: 2026-06-14
✓ ETHICAL PASS

Unknown MOAT
HIGH
Data Confidence: 100.0%
Convergence Score
Score pending — view screener
Market Regime
Analysis pending
Today's Read
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted ret...
2026-07-03
Full Daily Analysis

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$194.3B
Total market value of the company
Trailing P/E
10.37
Reasonably valued
Forward P/E
13.20
Based on estimated future earnings — lower means cheaper
Rev Growth
+24.0%
Year-over-year revenue change
Profit Margin
37.2%
How much profit the company keeps from each dollar of revenue
ROE
71.4%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$45.61
+4% from current price — median analyst estimate
Recommendation
BUY
Consensus view from 12 analysts covering this stock

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The c

https://www.novonordisk.com

Country: Denmark Employees: 67,900 Industry: Drug Manufacturers - General

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
24.1% PASS
Debt must be below 33% of total assets
Cash Ratio
4.9% PASS
Interest-bearing cash below 33% of assets
Receivables
1.1% PASS
Receivables below 49% of assets
Revenue Purity
1.0% PASS
Non-compliant revenue below 5% — any excess requires purification

Valuation

Fair Value Est.
$81.21
What our model estimates this business is worth per share
Margin of Safety
47.1%
Trading below fair value — margin of safety exists
Rating
OPPORTUNITY
Overall assessment combining ethics, valuation, and quality
Percentile
99.9th
Ranks in the top 0% of our 13,571 screened universe
Ethical Score
70.0
Valuation Score
70.0
Quality Score
90.0
Combined
77.0

Trading at $44 against a fair value of $81, a 45% discount. 37% profit margins. Passes all ethical screens. Ranks better than 98% of screened stocks.

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime
ACCUMULATION
Smart money appears to be building positions quietly
Sharpe Ratio
-0.856
Returns do not compensate for the risk — negative edge
Kelly Fraction
-0.0915
No positive edge detected — the data suggests staying out
Calmar Ratio
-0.547
Drawdown risk outweighs the returns — higher risk profile
Annual Return
-40.9%
Historical annualised return based on price data
Max Drawdown
-74.7%
Largest peak-to-trough decline — the worst it has been
HMM State
SIDEWAYS
Price consolidating — no clear directional bias
Days in State
44
How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta
0.35
Very low correlation to market moves
52W High
$78.38
44% below the year high
52W Low
$35.12
25% above the year low
Avg Volume
16,146,736
Average daily shares traded — higher means easier to buy and sell
Short Ratio
1.5
Days it would take all short sellers to cover — higher means more crowded
Short % Float
0.4%
Low short interest — limited bearish positioning
Div Yield
411.0%
Annual dividend as a percentage of the share price
EPS (TTM)
$4.23
Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity
72.09
Heavy leverage — higher financial risk if revenues decline
Current Ratio
0.79
Below 1 means short-term obligations exceed liquid assets — risk flag
Quick Ratio
0.54
Like current ratio but excludes inventory — stricter test
Gross Margin
83.2%
Revenue left after cost of goods — higher means pricing power
Operating Margin
61.6%
Profit from core operations before interest and tax
Free Cash Flow
$-12,039,249,920
Negative — the business is spending more than it generates
Revenue (TTM)
$327.8B
Total revenue over the last 12 months
Net Income
$122.0B
Profitable — the bottom line is positive

Analyst Coverage

Analysts
12
Target High
$63.86
Target Median
$45.61
Target Low
$40.10

What If You'd Bought NVO?

Period Price Then Price Return Divs/Share $1,000 Became Total Return
1 Month $46.40 -7.8% — $922 -7.8%
2 Months $37.52 +14.0% — $1,140 +14.0%
3 Months $36.67 +16.6% $1.28 $1,201 +20.1%
6 Months $48.51 -11.8% $1.28 $908 -9.2%
1 Year $75.67 -43.5% $1.86 $590 -41.0%
2 Years $134.33 -68.2% $3.47 $344 -65.6%
3 Years $73.03 -41.4% $4.84 $652 -34.8%
5 Years $37.93 +12.8% $6.53 $1,300 +30.0%
Dividends Collected Per Share
1 Year: $1.8590
3 Years: $4.8430
5 Years: $6.5260
$1,000 invested 1 year ago = 13.2 shares = $24.57 in dividends collected

Historical returns. Past performance does not guarantee future results. Prices from market close data.

Framework Review History

Timestamped framework reads — tracking how the analysis evolves over time

2026-07-03 ACCUMULATION $43.88 +0.0% Review #2

The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.

2026-07-02 ACCUMULATION $43.88 Review #1

The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.

Latest Analysis — NVO

Timestamped intelligence from our daily research pipeline

3 Jul 2026
16:49 UTC
Uncategorized
LMT — Deep Ticker Analysis | Framework Read 3 July 2026

Lockheed Martin (LMT) Case Study | Titan Protect * { margin: 0; padding: 0; box-sizing: border-box; } body { background: #0a0e14; color: #e0e0e0; font-family: 'Segoe UI', system-ui, -apple-system, sans-serif; line-height:...

3 Jul 2026
16:49 UTC
Uncategorized
ABBV — Deep Ticker Analysis | Framework Read 3 July 2026

AbbVie (ABBV) Case Study | Titan Protect * { margin: 0; padding: 0; box-sizing: border-box; } body { background: #0a0e14; color: #e0e0e0; font-family: 'Segoe UI', system-ui, -apple-system, sans-serif; line-height: 1.7;...

3 Jul 2026
16:49 UTC
Uncategorized
GS — Deep Ticker Analysis | Framework Read 3 July 2026

Goldman Sachs (GS) Case Study | Titan Protect * { margin: 0; padding: 0; box-sizing: border-box; } body { background: #0a0e14; color: #e0e0e0; font-family: 'Segoe UI', system-ui, -apple-system, sans-serif; line-height:...

3 Jul 2026
08:57 UTC
Uncategorized
TD — Deep Ticker Analysis | Framework Read 3 July 2026

Toronto-Dominion Bank (TD) - Case Study | Titan Protect *{margin:0;padding:0;box-sizing:border-box} body{background:#0a0e14;color:#c9d1d9;font-family:'Segoe UI',system-ui,-apple-system,sans-serif;line-height:1.7} .container{max-width:860px;margin:0 auto;padding:2rem 1.5rem} h1{color:#D8AF44;font-size:2rem;margin-bottom:0.3rem;line-height:1.3} h2{color:#D8AF44;font-size:1.35rem;margin:2rem 0 0.8rem;border-bottom:1px solid #2a2f3a;padding-bottom:0.4rem} p{margin-bottom:1rem;color:#c9d1d9} .meta{color:#8b949e;font-size:0.9rem;margin-bottom:2rem} .meta span{margin-right:1.5rem} .card{background:#1a1f2b;border:1px solid #2a2f3a;border-radius:8px;padding:1.5rem;margin:1.2rem 0} .card-title{color:#D8AF44;font-size:1rem;font-weight:600;margin-bottom:0.6rem}...

3 Jul 2026
08:57 UTC
Uncategorized
TCOM — Deep Ticker Analysis | Framework Read 3 July 2026

Trip.com (TCOM) - Case Study | Titan Protect *{margin:0;padding:0;box-sizing:border-box} body{background:#0a0e14;color:#c9d1d9;font-family:'Segoe UI',system-ui,-apple-system,sans-serif;line-height:1.7} .container{max-width:860px;margin:0 auto;padding:2rem 1.5rem} h1{color:#D8AF44;font-size:2rem;margin-bottom:0.3rem;line-height:1.3} h2{color:#D8AF44;font-size:1.35rem;margin:2rem 0 0.8rem;border-bottom:1px solid #2a2f3a;padding-bottom:0.4rem} p{margin-bottom:1rem;color:#c9d1d9} .meta{color:#8b949e;font-size:0.9rem;margin-bottom:2rem} .meta span{margin-right:1.5rem} .card{background:#1a1f2b;border:1px solid #2a2f3a;border-radius:8px;padding:1.5rem;margin:1.2rem 0} .card-title{color:#D8AF44;font-size:1rem;font-weight:600;margin-bottom:0.6rem} .highlight{color:#D8AF44;font-weight:600}...

3 Jul 2026
08:56 UTC
Uncategorized
SQM — Deep Ticker Analysis | Framework Read 3 July 2026

Sociedad Quimica y Minera (SQM) - Case Study | Titan Protect *{margin:0;padding:0;box-sizing:border-box} body{background:#0a0e14;color:#c9d1d9;font-family:'Segoe UI',system-ui,-apple-system,sans-serif;line-height:1.7} .container{max-width:860px;margin:0 auto;padding:2rem 1.5rem} h1{color:#D8AF44;font-size:2rem;margin-bottom:0.3rem;line-height:1.3} h2{color:#D8AF44;font-size:1.35rem;margin:2rem 0 0.8rem;border-bottom:1px solid #2a2f3a;padding-bottom:0.4rem} p{margin-bottom:1rem;color:#c9d1d9} .meta{color:#8b949e;font-size:0.9rem;margin-bottom:2rem} .meta span{margin-right:1.5rem} .card{background:#1a1f2b;border:1px solid #2a2f3a;border-radius:8px;padding:1.5rem;margin:1.2rem...

3 Jul 2026
08:56 UTC
Uncategorized
RY — Deep Ticker Analysis | Framework Read 3 July 2026

Royal Bank of Canada (RY) - Case Study | Titan Protect *{margin:0;padding:0;box-sizing:border-box} body{background:#0a0e14;color:#c9d1d9;font-family:'Segoe UI',system-ui,-apple-system,sans-serif;line-height:1.7} .container{max-width:860px;margin:0 auto;padding:2rem 1.5rem} h1{color:#D8AF44;font-size:2rem;margin-bottom:0.3rem;line-height:1.3} h2{color:#D8AF44;font-size:1.35rem;margin:2rem 0 0.8rem;border-bottom:1px solid #2a2f3a;padding-bottom:0.4rem} p{margin-bottom:1rem;color:#c9d1d9} .meta{color:#8b949e;font-size:0.9rem;margin-bottom:2rem} .meta span{margin-right:1.5rem} .card{background:#1a1f2b;border:1px solid #2a2f3a;border-radius:8px;padding:1.5rem;margin:1.2rem...

3 Jul 2026
08:56 UTC
Uncategorized
P — Deep Ticker Analysis | Framework Read 3 July 2026

Everpure Inc (P) - Case Study | Titan Protect *{margin:0;padding:0;box-sizing:border-box} body{background:#0a0e14;color:#c9d1d9;font-family:'Segoe UI',system-ui,-apple-system,sans-serif;line-height:1.7} .container{max-width:860px;margin:0 auto;padding:2rem 1.5rem} h1{color:#D8AF44;font-size:2rem;margin-bottom:0.3rem;line-height:1.3} h2{color:#D8AF44;font-size:1.35rem;margin:2rem 0 0.8rem;border-bottom:1px solid #2a2f3a;padding-bottom:0.4rem} p{margin-bottom:1rem;color:#c9d1d9} .meta{color:#8b949e;font-size:0.9rem;margin-bottom:2rem} .meta span{margin-right:1.5rem} .card{background:#1a1f2b;border:1px solid #2a2f3a;border-radius:8px;padding:1.5rem;margin:1.2rem 0} .card-title{color:#D8AF44;font-size:1rem;font-weight:600;margin-bottom:0.6rem}...

View all daily analysis →
Want deeper analysis on Novo Nordisk A/S?
Our framework analyses NVO daily across 19 analytical perspectives — positioning, macro, sentiment, volatility, options, sector rotation, and more. Members get the read 24 hours before anyone else.
Start Free — Explorer Access Open the Convergence Screener View Our Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-14

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry Indicators Options Calendar Composites Boycott Tracker Convergence Screener Fed Tracker Explore All Is It Halal? Earnings Calendar Dividend Screener Country Guides Glossary Join Free →

Get our weekly market brief free.